课题基金 / 基金详情

PROTECTION AGAINST VAGINAL CHALLENGE IN SIVDELTANEF-VACCINATED ANIMALS

PROTECTION AGAINST VAGINAL CHALLENGE IN SIVDELTANEF-VACCINATED ANIMALS
接种 SIVDELTANEF 疫苗的动物免受阴道感染的保护
批准号:
7958387
负责人:
Roger H Reeves
金额:
$19.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2010-04-30

项目摘要

项目成果

Roger H Reeves的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Lack of information on mechanisms of protection against HIV/SIV infection remains one of the leading obstacles to the development of a safe and effective AIDS vaccine. Vaccination of macaques with attenuated SIV strains has consistently proved to be the most effective means of inducing protection against pathogenic SIV challenge and offers the best available experimental model to define specific mechanisms responsible for protection. Previous studies from our group have provided evidence that SIV-specific CD8-positive T cell and humoral responses both contribute to protective immunity induced by SIVdeltanef but have not been able to assess their relative importance or the potential contributions of novel adaptive or innate immune responses to protection. The goal of this study is to utilize a number of novel techniques to carry out a comprehensive analysis of the role of adaptive and innate immune responses in mediating protection induced by SIVnef against vaginal challenge, one of the most important modes of HIV transmission. SIVnef infection resulted in significant increases in natural killer cells, SIV-specific CD8-positive T cell responses and antibody responses in the first 2-5 weeks after infection; these responses were associated with minimal protection against vaginal SIVmac251 challenge at 5 weeks after vaccination. Both humoral and cellular immune responses display progressive evidence of maturation from 5 to 20 weeks after vaccination, associated with substantial, though still incomplete, protection against vaginal SIVmac251 challenge. These studies results are yielding a comprehensive delineation of the signature characteristics of protective immunity against lentiviral infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chromosome 21 Elimination In A New Mouse Model of Down Syndrome
  • 批准号:
    9926296
  • 项目类别:
  • 资助金额:
    $20.47万
  • 财政年份:
    2019
  • 负责人:
    Roger H Reeves
  • 依托单位:
Hedgehog Treatment of Down Syndrome: Establishing Mechanisms
  • 批准号:
    8931797
  • 项目类别:
  • 资助金额:
    $19.74万
  • 财政年份:
    2014
  • 负责人:
    Roger H Reeves
  • 依托单位:
Hedgehog Treatment of Down Syndrome: Establishing Mechanisms
  • 批准号:
    8808144
  • 项目类别:
  • 资助金额:
    $24.3万
  • 财政年份:
    2014
  • 负责人:
    Roger H Reeves
  • 依托单位:
TEMPORAL ANALYSIS OF IMMUNE RESPONSES AND PROTECTION INDUCED BY SIVDELTANEF
  • 批准号:
    8357949
  • 项目类别:
  • 资助金额:
    $19.39万
  • 财政年份:
    2011
  • 负责人:
    Roger H Reeves
  • 依托单位:
海外基金